Micardis may be combined with other antihypertensives such as calcium-channel blockers or thiazide diuretics to achieve better blood-pressure control. However, co-administration with other renin-angiotensin system blockers (ACE inhibitors or other ARBs) is generally avoided because of increased risk of hypotension, hyperkalaemia and renal dysfunction.
Take the missed dose as soon as you remember, unless it is within 12 hours of the next scheduled dose. In that case, skip the missed dose and continue with your usual dosing time to maintain a consistent once-daily interval.
Telmisartan possesses partial agonist activity at peroxisome proliferator-activated receptor-γ (PPAR-γ), which may modestly improve insulin sensitivity and lipid profiles. These effects are modest and not a primary therapeutic goal; lifestyle measures and statin therapy remain the main approaches for cholesterol management.
ARBs, including telmisartan, do not significantly affect uric acid metabolism. They are generally considered safe for patients with gout, but any new medication should be discussed with a clinician, especially if the patient takes medications like allopurinol that may interact with renal function.
Telmisartan is primarily excreted via the bile and shows minimal renal clearance, making it a feasible option for patients on dialysis. Nonetheless, dose selection should be individualized and monitored closely for blood-pressure response and electrolyte balance.
In the UK, Micardis tablets are typically round, white to off-white, and bear the imprint “MICARDIS 20”, “MICARDIS 40” or “MICARDIS 80” corresponding to their strength. Inactive ingredients may include lactose, microcrystalline cellulose and magnesium stearate.
Telmisartan is not a controlled substance and is not screened for in standard occupational drug-testing panels. Its presence should not influence typical workplace drug-testing outcomes.
Most patients experience a measurable decline in systolic and diastolic pressures within 2 weeks, with maximal effect often reached after 4-6 weeks of consistent therapy. Follow-up appointments are essential to verify target attainment.
Telmisartan has a longer half-life and higher receptor affinity compared with many other ARBs, which may provide more consistent blood-pressure control with once-daily dosing. Clinical decisions, however, should consider individual patient response, cost, and formulary availability rather than relying solely on pharmacologic distinctions.
Micardis is a prescription (POM) medication that contains the active ingredient telmisartan. It belongs to the therapeutic class of Heart & Blood Pressure agents and is available in pill form in strengths of 20 mg, 40 mg and 80 mg. In the United Kingdom, Micardis is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is prescribed for the management of hypertension and certain cardiovascular conditions.
Telmisartan is an angiotensin II receptor blocker (ARB). It selectively blocks the binding of angiotensin II to the AT₁ receptor on blood vessels and the adrenal gland. By preventing this interaction, teltelmisartan:
The onset of blood-pressure reduction typically occurs within a few hours, with the peak effect seen after 2-4 hours. Telmisartan has a long half-life of about 24 hours, supporting once-daily dosing. Its oral bioavailability is approximately 50 % and it is largely excreted unchanged in the bile.
In the UK, Micardis is approved for the following indications:
These uses are supported by clinical guidelines from the National Institute for Health and Care Excellence (NICE) and reflected in the product’s Summary of Product Characteristics (SPC).
Current peer-reviewed evidence provides limited support for off-label uses of telmisartan. Some studies have explored its role in:
Because these indications are not approved by the MHRA, they should only be considered under specialist supervision with a clear risk-benefit assessment.
Absolute contraindications
Relative contraindications
Special populations
When initiating Micardis, clinicians should review all current medications, including over-the-counter products and herbal supplements.
Patients should avoid starting new medications or supplements without informing their healthcare provider.
Renal or hepatic impairment - Dose adjustments may be required; clinicians typically initiate therapy at 20 mg and titrate cautiously.
Patients should contact their prescriber if they experience persistent dizziness, marked swelling, or signs of kidney dysfunction (e.g., reduced urine output).
This article provides educational information about Micardis and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
